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Chronic exposure to ethanol produces a number of detrimental effects on behavior.
Neuroadaptive changes in brain structure or function underlie these behavioral effects and
may be transient or persistent in nature. Central to the functional changes are alterations in
the biology of neuronal and glial cells of the brain. Recent data show that ethanol induces
glial cells of the brain to produce elevated levels of neuroimmune factors including CCL2,
a key innate immune chemokine. Depending on the conditions of ethanol exposure, the
upregulated levels of CCL2 can be transient or persistent and outlast the period of ethanol
exposure. Importantly, results indicate that the upregulated levels of CCL2 may lead to
CCL2-ethanol interactions that mediate or regulate the effects of ethanol on the brain.
Glial cells are in close association with neurons and regulate many neuronal functions.
Therefore, effects of ethanol on glial cells may underlie some of the effects of ethanol
on neurons. To investigate this possibility, we are studying effects of chronic ethanol
on hippocampal synaptic function in a transgenic mouse model that expresses elevated
levels of CCL2 in the brain through enhanced glial expression, a situation know to occur
in alcoholics. Both CCL2 and ethanol have been reported to alter synaptic function in the
hippocampus. In the current study, we determined if interactions are evident between
CCL2 and ethanol at the level of hippocampal synaptic proteins. Two ethanol exposure
paradigms were used; the first involved ethanol exposure by drinking and the second
involved ethanol exposure in a paradigm that combines drinking plus ethanol vapor. The
first paradigm does not produce dependence on ethanol, whereas the second paradigm is
commonly used to produce ethanol dependence. Results show modest effects of both
ethanol exposure paradigms on the level of synaptic proteins in the hippocampus of
CCL2 transgenic mice compared with their non-transgenic littermate controls, consistent
with ethanol-CCL2 interactions. No evidence of toxic effects of CCL2 or CCL2-ethanol
interactions was observed. Taken together, these results support the idea that ethanol
induced astrocyte production of CCL2 can result in neuroadaptive changes that interact
with the actions of ethanol.
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INTRODUCTION
Emerging research indicates that an important effect of alcohol
(ethanol) on the brain is the induced production of neuroim-
mune factors including the chemokine CCL2 (Gruol, 2013).
Studies by Qin et al. (2008) showed increased levels of mRNA
and protein for CCL2 in the brain of mice subjected to either sin-
gle or repetitive ethanol exposure (10 days; 5 gm/kg, i.g.). In mice
subjected to repetitive ethanol exposure, the increased levels of
CCL2 persisted for days after withdrawal from ethanol treatment
(Qin et al., 2008), indicating that ethanol can have long-term
effects on CCL2 levels. Consistent with these results, Kane et al.
(2013a,b) reported that chronic ethanol exposure (6 gm/kg i.g. 10
days) increased levels of CCL2 mRNA in the hippocampus and
cerebellum of adult mice. In studies by Whitman et al. (2013),
i.g. administration of acute ethanol at a lower dose 2.75 gm/kg
did not increase levels of CCL2 mRNA in the brain at either
4 or 24 h after treatment, whereas 24 h after withdrawal from
chronic ethanol exposure (liquid diet) levels of CCL2mRNAwere
significantly increased in the brain and gradually declined to con-
trol levels over the following week. Studies by Flora et al. (2005)
showed that i.p. injection of ethanol (2 injections at 3 gm/kg body
weight) increased levels of CCL2 mRNA in the hippocampus but
not in the corpus striatum, suggesting regional differences in the
actions of ethanol on CCL2 production. Importantly, studies of
postmortem human brains by He and Crews (2008) showed that
specific areas of brains from post-mortem human alcoholics (lim-
bic regions) have a significantly higher concentration of CCL2
than brains from post-mortem human non-alcoholics.
Within the brain, CCL2 is primarily produced by astrocytes
and microglia, with upregulated production when the glia are
activated (Glabinski et al., 1996). Consistent with this source,
exposure of hippocampal-entorhinal cortex brain slice cultures to
ethanol (100mM; 72 h) resulted in a significant and progressive
increase (∼10 fold increase) in the levels of CCL2 mRNA (Zou
and Crews, 2010). Immunostaining of the brain slice cultures
showed prominent co-localization of CCL2 immunoreactivity
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with GFAP immunoreactivity, indicating that astrocytes were the
primary source of the ethanol-induced CCL2 production in this
preparation (Zou and Crews, 2010). In postmortem brains of
human alcoholics, morphological changes in microglia reflective
of activation were observed and these changes were associated
with upregulation of microglial proteins characteristic of neu-
roimmune activation (He and Crews, 2008). Microglia activation
is a hallmark of neuroimmune activation and is associated with
the production of chemokines including CCL2, proinflammatory
cytokines and other inflammatory mediators such as COX-2 and
iNOS (Blanco and Guerri, 2007; Suk, 2007).
Although research has identified that ethanol induces glial
activation and the production of CCL2 in the brain, informa-
tion on how CCL2 alone or in conjunction with ethanol exposure
affects the brain is still relatively limited. Results from several
recent studies involving exogenous application of CCL2 and stud-
ies in transgenic mice that express elevated levels of CCL2 in
the brain indicate that CCL2 can alter neuronal and synaptic
function. For example, studies by Zhou et al. (2011) showed
that acute exposure to CCL2 (2.5 nM) increased synaptic trans-
mission in hippocampal slices from adolescent mice by acting
through presynaptic mechanisms involving transmitter release.
Neuronal excitability was also increased by acute exposure to
CCL2 in this study. Acute exposure to CCL2 (10 nM) was also
reported to increase excitability in striatal neurons, as evidenced
by increased spike firing resulting from effects of CCL2 on mem-
brane leak channels (Guyon et al., 2009). In rodent cultured
neurons from various brain regions including the cortex, hip-
pocampus, hypothalamus, andmesencephalon, acute exposure to
CCL2 elicited Ca2+ transients (Banisadr et al., 2005), an effect
likely to alter neuronal function. Our studies showed that acute
CCL2 (25 nM) decreased excitability and enhanced Ca2+ tran-
sients elicited by mGluR1 agonists in cultured Purkinje neurons
(Van Gassen et al., 2005). CCL2 has been reported to block
the activation of T-type Ca2+ channels in rodent dorsal root
ganglia neurons (You et al., 2010) and to inhibit GABAA receptor-
mediated GABAergic responses in cultured spinal cord neurons
(Gosselin et al., 2005). Other studies showed neuronal expres-
sion and physiological actions of CCL2 in spinal ganglia. For
example, Belkouch et al. (2011) showed that acute exposure to
CCL2 (100 nM) increased Na+ channel activity in primary sen-
sory neurons. In transgenic mice that chronically express high
levels of CCL2 (∼3000 pg/ml by ELISA) in the hippocampus,
CA1 pyramidal neurons showed decreased excitability compared
with CA1 pyramidal neurons in non-transgenic littermate con-
trols (Nelson et al., 2011), whereas in another strain of CCL2
transgenic mice that express lower levels of CCL2 (∼1500 pg/ml
by ELISA) in the hippocampus, CA1 pyramidal neurons showed
increased excitability compared with CA1 pyramidal neurons in
non-transgenic littermate controls (Bray et al., 2013a), Taken
together, these studies support a role for CCL2 as a neuromod-
ulator with actions that vary depending CCL2 concentration and
cell type.
In contrast to CCL2, there is an extensive literature document-
ing the effects of ethanol on the brain. These studies show that
a primary mechanism through which ethanol affects the brain is
through regulation of neurotransmitter-gated and voltage-gated
ion channels that are essential for neuronal excitability and
synaptic function, such as the NMDA and GABAA receptors
and voltage-gated Ca2+ channels (VGCCs) (Crews et al., 1996;
Hoffman, 2003). By altering the function of these channels,
ethanol alters neuronal properties and ultimately influences the
functionality of the brain and consequently behavior. Short-term
exposure (hours) to ethanol produces only temporary func-
tional changes. However, repeated (i.e., chronic) ethanol expo-
sure produces persistent neuroadaptive changes that have serious
long-term consequences to brain function. For example, chronic
exposure to ethanol and/or withdrawal has been reported to
increase the density of NMDA receptor binding and elevate the
expression of specific NMDA receptor subunits in the brain
(Hoffman, 2003). Similar changes in the expression of VGCCs
have been reported following chronic alcohol exposure (Dolin
et al., 1987). The alterations in NMDA receptors and VGCCs are
thought to underlie the hyperexcitability and excitotoxicity asso-
ciated with withdrawal from chronic alcohol use (Gulya et al.,
1991; Whittington et al., 1995).
The action of ethanol to induce the production of CCL2 by
brain glial cells and the ability of both ethanol and CCL2 to alter
neuronal and synaptic function raises the possibility that the per-
sistently increased levels of CCL2 produced by chronic ethanol
exposure could interact with the effects of ethanol on the brain.
Several lines of evidence support this possibility. In studies by
Breese et al. (2008), rats exposed to CCL2 at weekly intervals (2
injections) by i.c.v. injection prior to chronic ethanol exposure
(a 5 day chronic ethanol diet) exhibited reduced social interac-
tion during ethanol withdrawal compared with rats that received
the same ethanol treatment but no CCL2. These results indicate
that CCL2 can sensitize mice to withdrawal-induced anxiety-like
behavior and suggest that CCL2-ethanol interactions can exacer-
bate the behavioral effects of ethanol. Studies by Blednov et al.
(2005) showed that mice lacking CCL2 and/or its receptor CCR2
exhibited lower ethanol preference and consumption than wild-
type control mice in a two-bottle choice behavioral paradigm.
These results were interpreted as implicating a role for CCL2 in
the motivational aspects of ethanol consumption. Our behavioral
studies in transgenic mice that persistently express elevated lev-
els of CCL2 in the brain through enhanced astrocyte expression
showed that the CCL2 transgenic (CCL2-tg) mice are resistant
to the acute ethanol-induced impairments in contextual learning
observed in the non-transgenic (non-tg) control mice (Bray et al.,
2013b). Consistent with this result, in studies of hippocampal
synaptic function in vitro acute ethanol (20–60mM) depressed
synaptic plasticity (long-term potentiation; LTP) in the non-tg
hippocampus but did not depress LTP the in the hippocam-
pus from CCL2-tg mice (Bray et al., 2013a). LTP is considered
to be a cellular mechanism of memory and learning (Lomo,
2003). These in vitro results are consistent with an ethanol-
CCL2 interaction that involves a protective effect of CCL2 against
detrimental effects of acute ethanol on hippocampal synaptic
function.
Astrocytes are a primary producer of CCL2 in the brain
(Ge et al., 2009). Therefore, targets of ethanol-induced astrocyte
produced CCL2 are likely to be the same as astrocyte pro-
duced CCL2 in the transgenic mice. This commonality could
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result in ethanol-CCL2 interactions under conditions of chronic
ethanol use when persistently elevated levels of ethanol-induced
CCL2 are likely to occur. To address this possibility, we have
investigated the effect of exposure to ethanol on the levels of
expression of cellular and synaptic proteins in the hippocam-
pus of CCL2-tg and non-tg mice. The elevated levels of CCL2
in the transgenic mice serve as a model for ethanol-induced ele-
vated levels of CCL2, as observed in chronic alcoholics (He and
Crews, 2008). Two chronic ethanol exposure paradigms were
used, (a) two bottle choice drinking (2BC) and (b) 2BC drink-
ing combined with chronic intermittent ethanol (CIE) exposure
(2BC/CIE paradigm). The latter paradigm has been shown to
produce ethanol dependence (Finn et al., 2007; Gilpin et al.,
2008; Yoneyama et al., 2008; Vendruscolo and Roberts, 2013).
CCL2-ethanol interactions were assessed in animals sacrificed
approximately 1 month after ethanol exposure, to identify per-
sistent effects of CCL2-ethanol interactions. Results from the
Western blot studies are reported here; results from companion
electrophysiological and behavioral studies will be reported in a
separate publication. The Western blot studies showed modest
effects of both ethanol exposure paradigms on the level of synap-
tic proteins in the hippocampus of CCL2-tg mice compared with
their non-tg littermate controls, consistent with ethanol-CCL2
interactions. These results support the proposal of interactions
between the effects of CCL2 and ethanol. These interactions do
not appear to include toxicity that is persistent in nature, as nei-
ther the chronically elevated levels of CCL2 nor CCL2-ethanol
interactions produced persistent alterations in several housekeep-
ing proteins in the hippocampus of CCL2-tg mice compared with
non-tg mice.
MATERIALS AND METHODS
ANIMALS
Mice with astrocyte-targeted overexpression of CCL2 (previously
known as monocyte chemoattractant protein-1 or MCP-1) were
obtained from Dr. Richard Ransohoff of the Cleveland Clinic
Foundation. The generation of the CCL2 transgenic line was
described previously (Huang et al., 2002). Briefly, the murine
CCL2 gene was placed under control of the huGFAP promoter
and purified GFAP-CCL2 fusion gene fragment was injected into
fertilized eggs of SWXJ (H-21q, s) mice. Transgenic animals and
their progeny were identified by analysis of tail DNA. The line
was later backcrossed onto a C57BL/6J background and main-
tained for several years by breeding heterozygous CCL2-tg mice
with wildtype C57BL/6J mice. Offspring were genotyped using
standard protocols as previously described (Huang et al., 2002).
DNA samples were prepared from cut tail tips of individual ani-
mals at weaning (21–28 days postnatal) using the Mouse Tail
Quick Extraction Kit (Pioneer Inc., San Diego, CA). Mice posi-
tive for the human GFAP-murine CCL2 transgene were identified
by PCR. Samples were prepared for PCR using the HotStart Taq
Master Mix with Loading Dye (Pioneer). All animal procedures
were performed in accordance with the Scripps Research Institute
and National Institutes of Health Guideline for the Care and Use
of Laboratory Animals. Animal facilities and experimental proto-
cols were in accordance with the Association for the Assessment
and Accreditation of Laboratory Animal Care.
ETHANOL EXPOSURE
Male and female CCL2-tg and non-tg littermate mice at approxi-
mately 3–4 months of age were used. The mice were divided into
control (i.e., ethanol–naïve) and two ethanol treatment groups.
The ethanol-treated mice were exposed to either: (a) two bottle
choice ethanol drinking (2BC) or (b) 2BC ethanol drinking com-
bined with CIE vapor exposure (2BC/CIE paradigm). 2BC with-
out vapor does not produce dependence on ethanol, whereas the
2BC/CIE paradigm is commonly used to produce ethanol depen-
dence (Becker and Lopez, 2004; Lopez and Becker, 2005; Finn
et al., 2007; Griffin et al., 2009). The experiments involved two
different 2BC exposure paradigms (see below). Results from the
groups exposed to the two 2BC paradigms were combined for the
present analyses and were considered to be ethanol-experienced
yet not dependent. The 2BC/CIE paradigm mice were analyzed
as a separate group because they had received ethanol vapor in
addition to 2BC drinking and had been made ethanol depen-
dent. All studies involved comparisons between CCL2-tg and
non-tg mice within a treatment group (i.e., ethanol naïve, 2BC
or 2BC/CIE).
Two bottle choice ethanol drinking (2BC)
This first 2BC protocol was adapted from that of Blednov et al.
(2012). Mice were acclimated for 1 week to individual housing.
Two drinking tubes were continuously available to each mouse
on Monday through Friday and fluid consumption was measured
daily. One bottle of water was available during weekends. Food
was available ad libitum and mice were weighed every week. After
4 days of water consumption (on Monday, off Friday; water in
both tubes), mice were offered 3% ethanol (v/v) vs. water on the
followingMonday-Friday. Tube positions were changed every day
to control for position preferences. Over the following 4 weeks
mice received 6, 9, 12, and 15% ethanol in this same manner.
Following this, mice received 15% ethanol for 2 h per day for 5
days. The quantity of ethanol consumed (g/kg body weight/24 or
2 h) was calculated for each mouse and averaged across each 4–5
days measurement period. Control animals received water rather
than ethanol. Ethanol drinking behavior (preference and con-
sumption) was similar for CCL2-tg and non-tg mice under the
conditions examined (choice conditions in non-dependentmice).
Chronic intermittent ethanol (CIE) protocol
The specific methodology used is provided on the INIA-
West website http://www.scripps.edu/cnad/inia/ under
“Methodology,” “SOP Chronic Intermittent Ethanol—Two
Bottle Choice Mouse Model PDF” (Becker and Lopez, 2004;
Lopez and Becker, 2005; Finn et al., 2007; Griffin et al., 2009). For
15 days (5 days per week for 3 weeks), 30min before the lights
were turned off, mice were singly housed for 2 h with access to
two drinking tubes, one containing 15% ethanol and the other
containing water (i.e., two bottle choice). Ethanol and water
consumption during these 2-h periods was recorded. Following
this baseline period, mice were divided, based on equal ethanol
and water consumptions in each genotype/sex, into two balanced
groups that were exposed to intermittent ethanol vapor (Vapor)
or control air (Air) in identical chambers. Following the baseline
period, the Vapor group was injected with 1.75 g/kg ethanol plus
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68.1mg/kg pyrazole (an alcohol dehydrogenase inhibitor used
to stabilize ethanol levels) and placed in the ethanol chambers
to receive intermittent vapor for 3 days (16 h vapor on, 8 h off).
Following each 16 h bout of vapor, mice were removed and tail
blood was sampled for blood ethanol determination. Target
blood ethanol levels were 150–225mg%. Following the third
day of exposure, mice were allowed 72 h of undisturbed time.
The Vapor mice were then given 5 days of 2-h access to bottles
containing 15% ethanol and water. The Air group (2BC, but
no vapor) was injected with 68.1mg/kg pyrazole in saline and
placed in chambers delivering air for the same periods as the
Vapor group and were also exposed to two bottle choice drinking
at the same time as the Vapor groups. The vapor/air exposure
and 5 days of 2 bottle choice testing was repeated another 2
times for a total of 3 rounds of vapor and two bottle choice
drinking. Results from the Air group mice were combined with
the above-mentioned 2BC mice for data analyses. The 2BC plus
vapor group (2BC/CIE) was analyzed separately.
PROTEIN ASSAYS
Protein assays were carried out on lysates prepared from hip-
pocampus of CCL2-tg and non-tg mice. The ethanol-exposed
mice were sacrificed approximately 1 month after the ter-
mination of ethanol exposure and were approximately 7–9
months of age at the time of sacrifice. To obtain the hip-
pocampi, mice were anesthetized with isoflurane and decapi-
tated. The brains were rapidly removed and immersed in chilled
artificial cerebral spinal fluid used for dissections (dACSF).
The composition of dACSF was 130.0mM NaCl, 3.5mM KCl,
1.25mM NaH2PO4, 24.0mM NaHCO3, 0.2mM CaCl2, 5.0mM
MgSO4, and 10.0mM glucose (all chemicals were purchased
from Sigma-Aldrich, St. Louis, MO). dACSF was bubbled con-
tinuously with 95% O2/5% CO2 (pH 7.2-7.4). The hippocam-
pus was removed from the brain, snap frozen on dry ice and
stored at −80◦C until use. Proteins were extracted by sonica-
tion in cold lysis buffer containing 50mM Tris-HCL, pH 7.5,
150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.5% NP-40, a
Complete Protease Inhibitor Cocktail Tablet (Roche Diagnostics,
Mannheim, Germany), and a cocktail of phosphatase inhibitors
(Na+ pyrophosphate, β-glycerophosphate, NaFl, Na+ orthovana-
date; all from Sigma-Aldrich). The samples were incubated on
ice for 30min, centrifuged at 13,860 g for 30min at 4◦C, and
the supernatants were collected. Protein concentration in the
supernatants was determined using the Bio-Rad Protein Assay Kit
(Bio-Rad, Hercules, CA). Aliquots were stored at −80◦C.
CCL2 levels in protein samples were determined by ELISA
using the Mouse CCL2 ELISA Ready-SET-Go! Kit (eBioscience,
Inc., San Diego, CA) following manufacturer’s instructions.
Western blot analysis of protein samples was carried out as pre-
viously described (Nelson et al., 2011). Briefly, equal amounts
of protein samples were subjected to SDS-PAGE using 4–12%
Novex NuPAGE Bis-Tris gels (Invitrogen) and transferred to
Immobilon-P membranes (Millipore, Billerica, MA). CCL2-tg
and non-tg protein samples from the same treatment group
were run on the same gel. Uniform transfer was confirmed
by Ponceau S staining (Pierce, Rockford, IL). Membranes were
washed and blocked in 5% casein. The membranes were exposed
to primary antibodies, washed, and then incubated in secondary
antibody coupled to horseradish peroxidase (HRP). Membranes
were stripped and reprobed for β-actin. Protein bands were visu-
alized by chemiluminescence and quantified by densitometry
measurements using NIH Image software (http://rsb.info.nih.
gov/nih-image/). To adjust for possible loading errors, the den-
sity of each band was normalized to the density of the band for
β-actin in the same lane. Normalized data from CCL2-tg mice
were then normalized to values from non-tg mice run on the
same gel. Data were combined according to treatment group and
reported as mean ± s.e.m. Data reported were obtained from
119 Western blots of hippocampus from 48 transgenic and 55
non-transgenic mice.
The following antibodies were used for Western blot stud-
ies: a monoclonal antibody to β-actin (#AC-15, 1:5000; Sigma-
Aldrich); a monoclonal antibody to glial fibrillary acidic protein
(#MAB360; 1:10,000; Millipore; GFAP); a monoclonal anti-
body raised against neuron specific enolase (#MAB314; 1:5000;
Millipore); a rabbit polyclonal antibody raised against a syn-
thetic peptide to the C-terminus of rat GAD 65/67 (#AB1511;
1:1000; Millipore); a purified rabbit antibody to synapsin 1 (#51-
5200; 1:5,000; Invitrogen Life Technologies, Grand Island, NY;
Syn 1); a rabbit monoclonal antibody to a synthetic peptide cor-
responding to amino acids 1–20 at the N-terminus of the mouse
vesicular GABA transporter (#NB110-55238; 1-2000; Novus
Biologicals, Littleton, CO; VGAT); a rabbit monoclonal anti-
body to Postsynaptic Density Protein 95 (PSD 95) produced by
immunizing rabbits with a KLH-coupled synthetic peptide cor-
responding to residues surrounding Gly99 of the human PSD95
(#3450; 1:500; Cell Signaling, Danvers, MA); a purified rabbit
polyclonal antibody raised against a synthetic peptide of the rat
GluA1 subunit of the AMPA receptor conjugated to KLH with a
cysteine added (#07-660; 1:500; Millipore); a rabbit monoclonal
antibody produced by immunizing rabbits with a synthetic phos-
phopeptide corresponding to residues surrounding Ser845 of the
human GluA1 subunit of the AMPA receptor (#8084; 1-500; Cell
Signaling; GluA1p845); a rabbit polyclonal antibody produced by
immunizing rabbits with a synthetic short amino acid sequence
containing phosphoryated Ser831 of the rat GluA1 subunit of the
AMPA receptor (#sc135698; Santa Cruz Biotechnology, Dallas,
Texas 75220; GluA1p831); a purified goat polyclonal antibody
raised against a peptide corresponding to an amino acid map-
ping the C-terminus of the human GluN1 subunit of the NMDA
receptor (sc-1467; 1:500; Santa Cruz Biotechnology); a puri-
fied rabbit polyclonal antibody raised against a synthetic peptide
from the 2nd cytoplasmic domain of human GluN2A subunit
of the NMDA receptor conjugated to an immunogenic carrier
protein (#ab84181;1-500; abcam, Cambridge, MA); a rabbit poly-
clonal antibody raised against a synthetic peptide mapping to
the N-terminus of the human GluN2B subunit of the NMDA
receptor (#ab65875; 1-500; abcam); a purified rabbit polyclonal
antibody raised against a carboxy terminus peptide of the rat
mGluR2/3 conjugated to BSA with gluteraldehyde (#AB1553;
1-1000; Millipore) a rabbit polyclonal antibody raised against
p44/p42 mitogen activated protein kinase (#61-7400; 1:5000,
Zymed, Carlsbad, CA, USA); a purified rabbit polyclonal anti-
body raised against a synthetic phospho-peptide (KLH-coupled)
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corresponding to residues around Thr202/Tyr204 of human
p44/p42 MAPK (#9101; 1:500; Technologies, Danvers, AM;
pp44/42 MAPK); a purified rabbit polyclonal antibody raised
against a synthetic peptide (KLH-coupled) corresponding to
the sequence of mouse STAT3 (AB#9132; 1:1000; Cell Signaling
Technologies).
STATISTICAL ANALYSIS
Statistical analysis of differences between CCL2-tg and non-
tg data was performed using the unpaired t-test. Statistical
significance was set at p < 0.05.
RESULTS
Neuroadaptive interactions between CCL2 and ethanol in the
hippocampus were determined at the level of protein expression
by comparing Western blots of CCL2-tg vs. non-tg hippocam-
pus from mice exposed to the same ethanol exposure paradigm.
Ethanol naïve mice were also studied. CCL2-tg and non-tg mice
were exposed to ethanol by voluntary ethanol drinking using
a two bottle choice paradigm (2BC) or a paradigm involving
both voluntary ethanol drinking and exposure to ethanol vapor
(2BC/CIE).
BLOOD ETHANOL CONCENTRATION
Because ethanol drinking varied over the exposure period, blood
ethanol levels (BEC) were not determined for the 2BC group.
BECs during the ethanol vapor exposure bouts did not differ
between non-tg and CCL2-tg mice. In non-tg mice average levels
were 166 ± 6mg/dl (n = 9) and in CCL2-tg mice average levels
were 176 ± 8mg/dl (n = 10).
CCL2 LEVELS
CCL2 levels in the hippocampus of ethanol naïve mice at dif-
ferent ages measured by ELISA are shown in Figure 1A. CCL2
levels were elevated in the hippocampus of CCL2-tg mice at all
ages studied (1–10 months of age) and were approximately 6 fold
FIGURE 1 | Levels of CCL2 in CCL2-tg and non-tg hippocampus
determined by ELISA. (A) CCL2 levels in ethanol naïve CCL2-tg and non-tg
hippocampus at ages ranging from 1 to 10 months. (B) Mean values for
CCL2 levels in CCL2-tg and non-tg hippocampus in the three treatment
groups. Ethanol naïve and ethanol exposed mice were approximately 7–9
months of age when CCL2 levels were determined (∼1 month after the
termination of ethanol exposure). Numbers in bars are the number animals
measured. ∗Statistically significant difference (p < 0.05, unpaired t-test)
from non-tg of the same treatment group.
higher in CCL2-tg hippocampus than in non-tg hippocampus.
There were no apparent differences in CCL2 levels as a conse-
quence of age (Figure 1A) or ethanol exposure (Figure 1B) for
either CCL2-tg or non-tg mice.
HOUSEKEEPING PROTEINS
Several housekeeping proteins were measured to identify poten-
tial changes in protein levels that would indicate toxic effects
as a result of elevated levels of CCL2 or CCL2-ethanol inter-
actions. Measurements were made of β-actin, a cytosketal pro-
tein expressed in all cells, GFAP, an astrocyte specific cytosketal
protein, and neuron specific enolase, a specific neuronal pro-
tein. No significant difference was observed for the levels of
these proteins between CCL2-tg and non-tg hippocampus for
ethanol naïve or the ethanol-exposed groups (Figure 2). Levels
of p44/42 MAPK, enzymes involved in many cellular processes
including synaptic function, were also measured and were sim-
ilar for CCL2-tg and non-tg hippocampus for ethanol naïve
and the ethanol-exposed groups (Figure 2). The level of STAT3,
another enzyme involved in many cellular processes, was mea-
sured in CCL2-tg and non-tg hippocampus from mice exposed
to the 2BC and 2BC/CIE paradigms. Again, there was no sig-
nificant difference between CCL2-tg and non-tg hippocampus
for the level of STAT3 in these two groups (2BC, CCL2-tg =
0.98 ± 0.07, n = 3, non-tg = 1.0 ± 0.10, n = 4; 2BC/CIE, CCL2-
tg = 0.98 ± 0.07, n = 10, non-tg = 1.0 ± 0.05, n = 4). These
results are consistent with a lack of persistent toxicity in the hip-
pocampus as a result of elevated levels of CCL2 or CCL2-ethanol
interactions.
SYNAPTIC PROTEINS
The level of expression of a variety of hippocampal presynap-
tic and postsynaptic proteins were examined by Western blot in
hippocampus of CCL2-tg and non-tg mice in the ethanol naïve
and ethanol-exposed mice. Several differences in the level of pre-
and post-synaptic proteins were observed between CCL2-tg and
non-tg hippocampus in the ethanol-exposed groups. Only one
difference was observed between CCL2-tg and non-tg hippocam-
pus for the ethanol naïve group (Figure 3, Table 1). In general,
the differences between CCL2-tg and non-tg hippocampus were
modest in nature.
Three presynaptic proteins were examined, synapsin 1 (Syn 1),
a synaptic vesicle protein, VGAT, the vesicular transporter for
the inhibitory transmitter GABA, and GAD65/67, the synthetic
enzyme for GABA. The differences were: (a) a significantly lower
level of Syn 1 in CCL2-tg hippocampus compared with non-
tg hippocampus for the 2BC group, a difference that was not
observed in the ethanol naïve or 2BC/CIE groups, (b) a sig-
nificantly lower level of GAD65/67 in CCL2-tg hippocampus
compared with non-tg hippocampus in the ethanol naïve group,
a difference that was not observed in the 2BC or 2BC/CIE groups
and (c) a significantly higher level of VGAT in CCL2-tg hip-
pocampus compared with non-tg hippocampus for both the 2BC
or 2BC/CIE groups, a difference that was not observed in the
ethanol naïve group.
The level of several postsynaptic proteins involved in synaptic
transmission were alsomeasured including PSD95, a postsynaptic
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FIGURE 2 | Levels of housekeeping proteins in CCL2-tg and non-tg
hippocampus determined by Western blot. Values are mean ± SEM.
Numbers in bars are the number of animals studied. Representative Western
blots are shown above the respective bar. Top blot is the protein indicated for
the graph; bottom blot (arrow) is β actin in the same lane. Numbers in bars
are the number of animals measured. n, non-tg; t, CCL2-tg.
scaffolding protein at excitatory synapses, GluA1, a subunit of
the AMPA receptor, GluN1, GluN2A and GluN2B, subunits
of the NMDA receptor, and the alpha subunit of Group II
metabotropic glutamate receptors (mGluR2/3, the antibody rec-
ognizes the alpha subunit of both receptors; the dimer was
measured). Two phosphorylated forms of GluA1 that have
been shown to play an important role in synaptic plastic-
ity (Sanderson et al., 2008) were also measured, GluA1p831
and GluA1p845 (Soderling and Derkach, 2000; Lee et al.,
2010).
Several differences were observed between CCL2-tg and non-
tg hippocampus in the 2BC and/or 2BC/CIE groups that were not
observed in the ethanol naïve group including (Figures 3B,C):
(a) a significantly higher level of GluA1 and GluN2B in CCL2-
tg hippocampus compared with non-tg hippocampus in the 2BC
group, a difference that was not observed in the ethanol naïve
or 2BC/CIE groups, (b) a significantly higher level of GluN1 and
GluA1p831 in CCL2-tg hippocampus compared with non-tg hip-
pocampus in the 2BC group, a difference that was not observed
in the ethanol naive or 2BC/CIE groups, (c) a significantly lower
level of mGluR2/3 in CCL2-tg hippocampus compared with non-
tg hippocampus in the 2BC and 2BC/CIE treatment groups, a
difference that was not observed in the ethanol naïve group, and
(d) a significantly lower level of GluA1p845 in CCL2-tg hip-
pocampus compared with non-tg hippocampus in the 2BC/CIE
group, a difference that was not observed in the ethanol naïve or
2BC groups. There was no significant difference in the levels of
PSD95 or GluN2A between CCL2-tg and non-tg hippocampus
for the ethanol naïve, 2BC or 2BC/CIE groups (Figures 3B,C).
Results from the Western blot studies are summarized in
Table 1.
DISCUSSION
In the current study we used a transgenic mouse model that
expresses elevated levels of CCL2 in the brain to determine if per-
sistently elevated levels of CCL2 results in neuroadaptive changes
that interact with the effects of ethanol exposure. Ethanol is
known to induce glial cells of the brain including astrocytes to
produce CCL2, an effect that presumably explains the elevated
levels of CCL2 in the brains of post-mortem human alcoholics
(He and Crews, 2008). Our previous studies using this transgenic
model showed interactions between the neuroadaptive effects of
CCL2 and the effects of acute ethanol on synaptic plasticity (Bray
et al., 2013a). In these studies, the elevated levels of CCL2 pro-
tected against the effects of acute ethanol on synaptic plasticity
(i.e., LTP).
Studies by others have suggested that ethanol-induced pro-
duction of neuroimmune factors contributes to the detrimental
effects of ethanol on the brain such as toxicity (Crews, 2012).
To test for this possibility in the CCL2-tg model we examined
the level of several neuronal and glia housekeeping proteins,
including β-actin, GFAP, enolase, p42/44 MAPK and STAT3.
Levels of these proteins would be expected to be altered as a
consequence of cell injury or death. Results showed no differ-
ence in the levels of these proteins between CCL2-tg and non-tg
hippocampus for either the ethanol naïve or ethanol exposed
groups, suggesting that neither CCL2 nor CCL2-ethanol inter-
actions produce persistent toxicity, at least under the conditions
of our experiments. However, transient injury could have been
produced by ethanol-CCL2 interactions that recovered before
our measurements were made at approximately 1 month after
termination of ethanol exposure. In our studies, modest levels
of ethanol exposure were used (BEC <200mg/dL), whereas in
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FIGURE 3 | Levels of synaptic proteins in CCL2-tg and non-tg
hippocampus determined by Western blot. Values are mean ± SEM.
Numbers in bars are the number of animals studied. Representative Western
blots are shown above the respective bar graph. Top blot is the protein
indicated for the graph; bottom blot (arrow) is β actin in the same lane.
Numbers in bars are the number of animals measured. n, non-tg, t, CCL2-tg.
∗statistically significant difference (p < 0.05, unpaired t-test) from non-tg of
the same treatment group.
studies where detrimental effects of CCL2-ethanol interactions
were proposed, higher concentrations of ethanol were used. At
higher ethanol concentrations CCL2 may act in concert with
ethanol or other factors (e.g., glutamate) to produce neurotoxicity
or other actions. Thus, the consequences of interactions between
CCL2 and ethanol are likely to depend on a number of factors
such as ethanol concentration, ethanol exposure paradigm and
brain region. The lack of evidence for toxic effects of CCL2 alone
observed in this study is consistent with our previous studies of
mice at 2–5 months of age. The CCL2-tg mice show little or no
brain pathology compared with the non-tg mice as assessed by
electrophysiological recordings, Western blot analysis of protein
expression and behavioral studies (Bray et al., 2013a).
Because astrocytes and microglia are in close association with
synapses (Bessis et al., 2007; Halassa et al., 2007) and dynami-
cally interact with neurons to influence synaptic transmission and
plasticity (Ben Achour and Pascual, 2010; Pannasch et al., 2011;
Tremblay and Majewska, 2011), ethanol induced glial production
of CCL2 could be an important aspect of the effects of ethanol
on synaptic function. Our studies of CCL2-tg and non-tg hip-
pocampus in the ethanol naïve group showed that elevated levels
of CCL2 alone results in neuroadaptive changes in the level of one
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Table 1 | CCL2 and CCL2-ethanol interactions affecting hippocampal
protein levels.
Protein Treatment group*
Control 2BC 2BC/CIE
β-actin None None None
GFAP None None None
Enolase None None None
P44/42 MAPK None None None
Synapsin 1 None  None
VGAT None  
GAD65/67  None None
PSD95 None None None
GluA1 None  
GluA1p831 None  None
GluA1 p845 None None 
GluN1 None  None
GluN2A None None None
GluN2B None  
mGluR2/3 None  
*For each group, CCL2-tg is compared to non-tg;  =CCL2 tg > non-tg;
 =CCL2 tg < non-tg; None, no significant difference between CCL2-tg and
non-tg.
important synaptic protein, GAD 65/67. This result is consistent
with the ability of astrocyte produced CCL2 to influence synapses,
although in this case the change was modest. In contrast, a
number of differences in the levels of hippocampal proteins
were observed between CCL2-tg and non-tg hippocampus of the
ethanol exposed animals, indicating interactions between ethanol
and CCL2 that produced neuroadaptive changes. Thus, the lev-
els of VGAT, GluA1 and GluN2B were increased and mGluR2/3
was decreased in CCL2-tg hippocampus compared with the non-
tg hippocampus in both the 2BC and 2BC/CIE treatment groups.
In addition, levels of GluN1 and GluA1p831 were increased and
GluA1p845 and Syn 1 were decreased in CCL2-tg hippocam-
pus compared with non-tg hippocampus in the 2BC treatment
group.With the data currently available, it is not possible to deter-
mine if similar changes also occurred in non-tg hippocampus of
ethanol-exposed mice but to a lesser extent than CCL2-tg hip-
pocampus. Studies in which ethanol naïve and ethanol exposed
samples are run on the same Western blot are needed to address
this issue, but were not pursued due to limited sample size. In
addition, it is unclear why some changes were observed in the
2BC group but not the 2BC/CIE group. It may be that for these
proteins both CCL2-tg and non-tg hippocampus were similarly
affected by the 2BC/CIE exposure paradigm and thus changes
would not be evident when comparisons were made between
CCL2-tg and non-tg hippocampus. Alternatively, changes pro-
duced by 2BC/CIE treatment were transient and not evident at the
post ethanol exposure time period examined in this study. Future
studies will be needed to address these possibilities. Future stud-
ies will also be required to identify the mechanisms underlying
the interactions between ethanol and CCL2. This interaction is
likely to involve alterations in the expression of target receptors
for CCL2 or the activation of downstream signaling pathways.
However, taken together, results from the 2BC studies indicate
that even moderate levels of prolonged ethanol exposure can
interact with the effects of persistently elevated levels of CCL2 to
cause neuroadaptive changes.
Results from the current studies are consistent with previ-
ous studies showing the ability of chronic ethanol exposure
paradigms to result in increased levels of synaptic proteins. For
example, GluA1 is increased by chronic ethanol exposure in rat
cortical cultures (Chandler et al., 1999) and other preparations
(Holmes et al., 2013). Similarly, a number of studies have shown
that chronic ethanol exposure and withdrawal results in elevated
levels of NMDA receptor subunits and synaptic responses in the
hippocampus and other brain regions (Nelson et al., 2005; Qiang
et al., 2007; Nagy, 2008). VGAT has also been reported to be
increased by chronic ethanol exposure in studies involving a cul-
ture preparation of cortical neurons (Zink and Spanagel, 2005).
However, the changes in the level of synaptic proteins produced
by ethanol exposure similar to that used in our studies are typi-
cally transient in nature (Roberto et al., 2006; Clapp et al., 2010;
Pian et al., 2010), whereas the interactions between CCL2-ethanol
observed in our study were evident 1 month following termina-
tion of ethanol exposure. These results suggest that CCL2-ethanol
interactions can produce changes similar to that of ethanol alone
but that the changes are more persistent in nature.
Several studies have shown that ethanol exposure increases the
levels of CCL2 in the brain (Flora et al., 2005; He and Crews,
2008; Qin et al., 2008; Kane et al., 2013a). Measurement of CCL2
levels in the hippocampus of control mice by ELISA showed
approximately a 6 fold higher concentration of CCL2 in CCL2-
tg hippocampus compared with non-tg hippocampus at all ages
studied. However, alterations in the levels of CCL2 levels by
ethanol treatment were not evident for either the non-tg or CCL2-
tg hippocampus. These results suggest that our ethanol exposure
paradigm does not result in persistently elevated levels of CCL2,
presumably due to the modest ethanol BECs achieved. However,
information on trafficking of CCL2 in the brain is limited and the
rate of production and relative level of stored vs. secreted CCL2
are unknown and could be affected by ethanol exposure in a man-
ner not detectable by our ELISA measurements. Because ethanol
was not on board when measurements of protein levels were
made, the ethanol-CCL2 interactions observed in our studies are
considered to reflect persistent neuroadaptive changes that once
established do not require the presence of ethanol for continued
expression, at least for a 1 month period following withdrawal
from ethanol.
Expression of CCL2 in the transgenic mice is under control
of the GFAP promoter. Astrocytes start to produce GFAP about 1
day postnatal and expression continues throughout the lifetime of
the animal (Kim et al., 2011). Our measurements of CCL2 levels
in CCL2-tg mice showed elevated levels at the earliest ages mea-
sured, 1 month postnatal. Thus, results from the CCL2-tg model
are likely to be most relevant to effects of chronic ethanol use that
starts early in the lifespan, such as the juvenile or adolescent stage
of life, a pattern of ethanol use that has significant risk for devel-
oping ethanol dependence and is currently an important societal
issue (Hingson et al., 2006; Foltran et al., 2011).
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